Newsflash: FDA Denies Approval of Weight-loss Drug

FDA Denies Approval of Weight-loss Drug: The manufacturer of the drug Contrave, a combination of naltrexone plus buproion was issued a response letter from the FDA which required the manufacturers to conduct a randomized, double blind, placebo-controlled trial before the new drug application can be approved.